Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ: PASG )

0.5600 +0.0368 (+7.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Passage Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio's Earnings: A Preview
Via Benzinga
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
From Passage Bio
Via GlobeNewswire
Expert Ratings for Passage Bio
Via Benzinga
Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder
Via Benzinga
Passage Bio: Q1 Earnings Insights
Passage Bio (NASDAQ:PASG) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
From Passage Bio
Via GlobeNewswire
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
From Passage Bio
Via GlobeNewswire
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Passage Bio
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
From Passage Bio
Via GlobeNewswire
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
From Passage Bio
Via GlobeNewswire
Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)
From Newman Ferrara LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
  
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Passage Bio Commences Initial-Stage Brain Disorder Study
Passage Bio (NASDAQ: PASG) has dosed the first patient in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin... 
Via Benzinga
Preview: Passage Bio's Earnings
Passage Bio (NASDAQ:PASG) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Passage Bio... 
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.